Rather than recognizing specific campaigns, the Pharmaguy™ Pioneer Award gives kudos to a pharmaceutical executive or team who has 'pioneered' in the use of social media or mobile for marketing, research, patient support, or corporate communications purposes.
You have to give kudos to the good doctors and policy makers of the American Medical Association for trying over the course of many to ban or in some way curtail direct-to-consumer drug ads by pharmaceutical companies. The latest effort focuses on drug price transparency in ads. Will it succeed where the other efforts have failed?
Pharmaguy™ is a Pharma Marketing Pundit & Critic, Blogger & Publisher of Pharma Marketing News
In this 5-minute audio snippet, Thomas P. Stossel, M.D., visiting scholar at the American Enterprise Institute for Public Policy Research, talks about what he calls the 'Conflict-of-Interest Narrative' or Myth, which is the subject of his new book, PharmaPhobia.
In this 3-minute audio snippet, Shona L. Davies, Communications & Programme Leader, Univadis, and Sean Nicholson, Senior Director, Social Media, Intouch Solutions, define what they mean by social media
In this 3-minute audio snippet, Peter Houston, founder of Flipping Pages Media Ltd, discusses the pros and cons of Tumblr and whether it is possible for pharma marketers to get involved with Tumblr. Is it too Early?
Pharmaguy's Social Media Timeline
In this 4-minute audio snippet, Jerry Matczak, Community Manager for the Lilly Clinical Open Innovation Team, explains how the Internet, transparency, sharing innovation, and engaging patients in online communities can change how pharmaceutical companies do research.
Pharmaguy™ is a Pharma Marketing 'Constructive' Critic, Blogger & Chief Pundit at Pharmaguy.com
In this 4-minute audio snippet, Roland Andersson, Director for Accenture's Life Sciences R&D practice, and Thomas Krohn, Director, Clinical Open Innovation, Eli Lilly, discuss the Transcelerate Biopharma initiative, the goals of which are to increase compliance and the productivity of clinical trials.